Bjornevik 2022 — EBV as a necessary cause of MS

One-paragraph summary

Longitudinal analysis of >10 million U.S. military personnel with serial blood samples banked across years of service. Of the cohort, 801 developed multiple sclerosis. The risk of MS increased 32-fold (HR 32.4, 95% CI 4.3–245.3) after EBV seroconversion compared to remaining EBV-seronegative; no comparable risk increase was seen with cytomegalovirus seroconversion (negative control for general viral seroconversion). Serum neurofilament-light (NfL) elevation, an early marker of neuroaxonal injury, occurred only after EBV seroconversion and not before. Together: EBV is the strongest known causal driver of MS at the population level, and is a near-necessary condition for the disease — although not sufficient (only a small fraction of EBV-seropositive individuals develop MS, implicating additional triggers). Bjornevik et al do not assert a specific molecular mechanism, but a leading candidate is EBV-driven epigenetic reprogramming of latently-infected B cells, producing pathogenic autoantibody-secreting plasma cells against CNS antigens (B-cell molecular mimicry; subsequent work by the same group identified GlialCAM as a key cross-reactive target). For this project, the paper functions as the cross-condition empirical anchor for the viral-genome-modification framework: EBV's necessity for MS provides the precedent for the project's working hypothesis that durable post-viral genome-state modifications (HERV reactivation, EBV B-cell reprogramming, SARS-CoV-2 LINE-1 integration) are foundational drivers of post-viral chronic conditions including FM.

Claims as triples

• viral_infection — causes → multiple_sclerosis [evidence: HR 32.4 for MS post-EBV-seroconversion; confidence: established]
• viral_infection — bridges → autoantibody_mediated_pain [evidence: EBV B-cell reprogramming → autoantibody production model; confidence: bridging]
• NfL — predicts → multiple_sclerosis [evidence: NfL elevation only post-EBV-seroconversion; confidence: emerging]
• viral_infection — bridges → fm_autoimmune [evidence: cross-condition extrapolation; confidence: bridging]
• viral_infection — bridges → me_cfs [evidence: EBV is also major ME/CFS trigger in published cohort studies; confidence: bridging]

Methods note

Prospective longitudinal cohort, U.S. military personnel with mandatory routine sera collection (~5.4M samples per year). 801 incident MS cases identified via medical records; matched-control nested-case design with 1,566 controls. EBV serostatus determined by anti-VCA IgG. NfL measured in pre-symptomatic samples by Simoa single-molecule array. Hazard ratios computed by conditional logistic regression. Pre-registered analytical plan; no significant data dredging.

Limitations

• Population is military, predominantly young adult, and predominantly male — generalizability to general FM patient population (which is 3:1 to 9:1 female and median age 35-55) is by extrapolation only.
• EBV-MS association is correlational at the molecular-mechanism level. Bjornevik et al establish necessity but not the specific molecular pathway. Subsequent work (Lanz et al 2022 Nature) identified anti-GlialCAM antibodies as the cross-reactive target, but the chain from EBV infection → reprogrammed B cells → pathogenic antibody production is still incomplete in molecular detail.
• Direct relevance to FM is bridging, not established. The project's claim that EBV-driven B-cell reprogramming may produce anti-SGC IgG in FM is plausible by analogy but not demonstrated. Q33 (EBV serology in anti-SGC-IgG-positive FM patients) is the obvious test.

Open questions raised

• Does EBV serostatus correlate with anti-SGC IgG positivity in FM patients? (Q33; tractable in any stored-serum FM cohort.)
• Does GlialCAM cross-reactivity, the mechanism Lanz 2022 identified for MS, also operate in FM patients? FABP7+ satellite glial cells (Seefried 2025) are a distinct candidate; whether GlialCAM and FABP7+ SGC antigens overlap antigenically is open.
• Is HHV-6 reactivation an alternative or co-occurring upstream driver in FM? HHV-6 is implicated in some ME/CFS literature; FM-specific HHV-6 evidence is limited.

Triangulation notes

• Anchors the viral-genome-modification framework cross-conditionally. The project's viral-genome-modification-hypothesis.md synthesis document and white paper §6.4 lean on this paper's "EBV is necessary for MS" finding as the empirical precedent for durable post-viral genome modification. Ingestion converts rhetorical-citation into evidence-backed triples.
• Strengthens B7 bridge (HERV ↔ FM autoimmune). EBV is a documented HERV-W ENV reactivation trigger; if EBV is necessary for MS via B-cell reprogramming, an analogous EBV-driven HERV-W ENV reactivation pathway is plausible for FM-autoimmune subset.
• Compatible with the H1 chain. EBV-driven plasma-cell reprogramming would produce the same pathogenic IgG that Goebel 2021 demonstrates by passive transfer, with EBV as the upstream trigger. Combined with Fluge & Mella 2025 (daratumumab plasma-cell depletion → ME/CFS improvement), the unified model is: EBV → reprogrammed long-lived plasma cells → autoantibody production → FM-autoimmune phenotype, with daratumumab interrupting the production step.

Bridges

• B7 strengthened — HERV ↔ FM autoimmune via reactivated HERV-W ENV. EBV is a documented HERV-W ENV reactivator.
• B8 strengthened — schizophrenia subset ↔ FM via shared viral substrate. Sighencea & Trifu 2025 documents the viral-pathogenesis framework in schizophrenia; Bjornevik 2022 documents it in MS; the framework is therefore cross-condition-validated.
• Implicit B11 candidate — MS ↔ FM via shared EBV-driven plasma-cell reprogramming. Both are responsive to plasma-cell-depletion therapies (daratumumab in ME/CFS pilot; ocrelizumab/rituximab in MS); both have post-viral onset clusters; the molecular mechanism may be substantially shared.